Skip to content
Loading…
Axiom Biosciences is considering an initial public offering in Hong Kong, a rare move for an American biotechnology firm, and one that would help it tap China’s booming clinical development capabilities.
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.